DPX-Survivac and Checkpoint Inhibitor in DLBCL

NCT03349450 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Adult Diffuse Large Cell Lymphoma
Recurrent
Adult Refractory Diffuse Large B-Cell Lymphoma

Interventions

BIOLOGICAL: DPX-Survivac
BIOLOGICAL: Pembrolizumab
DRUG: Cyclophosphamide 50mg

Sponsor

Sunnybrook Health Sciences Centre

Collaborators

[object Object]
[object Object]